Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lb-dtk-mv

Preclinical

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Infection

NCT07685457

PreclinicalRecruiting

Infection

NCT07670468

Clinical

Trials by Indication[1]

Infection2 trials

A Prospective Clinical Study to Evaluate the Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.

Recruiting·LLucasBio·Preclinical·NCT07685457·6 enrolled

A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

Recruiting·LLucasBio·Preclinical·NCT07670468·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lb-dtk-mv. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lb-dtk-mv. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — LucasBio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: LLucasBio

Related News